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Abstract
Background: Up to 40% of infants with persistent pulmonary hypertension (PPHN) remains refractory to
conventional therapies, and extracorporeal membrane oxygenation (ECMO) is offered as an effective support for
this group. However, ECMO is a highly invasive and risky procedure with devastating complications such as
intracranial hemorrhage (ICH). In this study, we aimed to determine the risk factors for ICH in infants with PPHN.
Methods: A case-control study of patients admitted to the pediatric intensive care unit (PICU) with PPHN requiring
ECMO support was conducted. The study was carried out at a 25-bed PICU in large urban tertiary care children’s
hospital. A total number of 32 subjects were studied. Patients with and without ICH during ECMO were evaluated
for activated clotting time (ACT), heparin dosing, platelet count, coagulation profile such as activated partial
thromboplastin time (aPTT), prothrombin time (PT), international normalized ratio (INR), fibrinogen level, vital signs
including heart rate and mean arterial pressure (MAP), transfusion history, gestational age, and severity of pre-ECMO
illness as possible risk factors.
Results: Low fibrinogen level (115 ± 13 mg/dl) and low platelet counts (37.4 ± 18.3 Thousand/μl) were associated
with higher incidence of ICH (p = 0.009 and p = 0.005, respectively). Elevated MAP (69 ± 4.34 mmHg) was also
noticed in ICH patients (p = 0.006).
Conclusions: Results demonstrated that low fibrinogen level and low platelet count were associated with ICH in
PPHN patients on ECMO. While on ECMO support, maintaining fibrinogen and platelet counts within normal ranges
seems crucial to prevent ICH in PPHN patients. This is the first report identifying low fibrinogen level among the risk
factors for ICH in infants with PPHN on ECMO support.
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Background
Extracorporeal membrane oxygenation (ECMO) is an
advanced support for patients who fail to respond to
conventional therapy [1]. With ECMO support, survival
rate has been improved for many life-threatening conditions related to respiratory failure over the years [1,2].
The overall survival rate for neonates with respiratory
failure have been treated with ECMO was reported to be
79.7%, and the survival rate for persistent pulmonary
hypertension (PPHN) patients was reported as 79.4% [2].
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Occurring in 1.9 in 1,000 live births, PPHN is a condition
where there is a failure of normal circulatory transition
after birth [3]. As a result, the normal drop in pulmonary
vascular resistance (PVR) fails to take place after birth
leading to hypoxemia [4]. Both non-invasive and invasive
mechanical ventilation as well as inhaled nitric oxide are
used to provide adequate tissue oxygenation until PVR
drops and normal circulatory dynamics are established
[5]. Despite improvements in these conventional therapies, up to 40% of infants with PPHN remain refractory
to therapy. For this group of patients, ECMO has been
offered as an effective therapy since its adoption in the
1980s [3,5].
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Despite its success, ECMO remains a highly invasive
and risky procedure. In the neonatal population, one
of the most devastating complications is intracranial
hemorrhage (ICH) [1,6]. The need for anticoagulation
in combination with the immature neonatal brain parenchyma makes the risk of ICH particularly high in
this population. In previous studies, intracranial complications were reported as 25% to 50% with a survival rate
of 43% [6].
Tubings and membranes of ECMO circuits are risk
factors for the activation of the coagulation system [7].
Unfractionated heparin (UFH) is used in to prevent clots
in ECMO circuit and the complications related to clot
formation in patients. It is crucial to monitor the level of
anticoagulation therapy closely to prevent the complications such as ICH as well as to track biochemical parameters such as activated partial thromboplastin time (aPTT),
activated clotting time (ACT), and anti-factor Xa (anti-Xa)
activity [7].
Relying on a single method has drawbacks. For example,
PTT is used to determine the deficiencies of various coagulation factors and to monitor the heparin treatment.
Prolonged PTT could be caused by many factors including
liver diseases, deficiencies in coagulation factors and vitamin K, disseminated intravascular coagulation, etc.
Activated coagulation time (ACT) test is another
method that is used for monitoring heparin treatment
and is used with fresh blood at the bedside. In experienced
hands, ACT produces reliable results. However, preanalytical conditions such as the presence of hemolysis
and suboptimal specimens might adversely affect the
outcome.
A chromogenic assay named anti-Xa is utilized in
quantifying UFH level. Factors such as free hemoglobin,
bilirubin, and triglycerides in plasma may decrease the
sensitivity of anti-Xa test [7].
Taken together, there is a need for a better delineation
of the factors causing bleeding complications during the
ECMO support [1]. The objective of the present study
was to investigate the occurrence of ICH and to identify
risk factors in neonates with PPHN.

Methods
We retrospectively reviewed charts of infants between
1997 and 2010 and included all infants with PPHN
diagnoses who required ECMO support. Infants who
received ECMO support for all other pathologies such
as meconium aspiration syndrome, congenital diaphragmatic hernia, acute respiratory distress syndrome, sepsis/pneumonia, or cardiac pathology were excluded. The
reason for the exclusions was to study a uniform group
of subjects. The aim was to reach a better comparison
between patients with the same pathology. Different
pathologies may affect coagulation system differently

Page 2 of 5

such as sepsis where patients may be more prone to
develop disseminated intravascular coagulation or to bleeding post cardiac surgery. It is hoped that the uniformity of
the subject might empower the analysis and the conclusion
drawn from the study.
Data collection included: demographic information on
age, sex, birth weight, ethnicity, type of ECMO, and duration on ECMO. Hourly ACT levels and heparin infusion
doses for the first 12 h of ECMO and maximum ACT
levels and heparin infusion doses for 5 days on ECMO for
both groups were also collected. Coagulation profile for
a-PTT, prothrombin time (PT), international normalized ratio (INR), and fibrinogen and platelet levels were
analyzed. In our unit, the anticoagulation protocol for
ECMO dictates that unfractionated heparin be used and
infusion is given directly to ECMO circuit via an infusion port located before the bladder. The heparin infusion rate is determined by patient’s weight (in kg) ×
desired unit/kg/h (concentration of drip: 50 units/ml).
We check ACT hourly for a target value of 200–225 s.
Target ACT values were adopted from Extracorporeal
Life Support Organization (ELSO) guidelines [8]. All
ACT levels are obtained from the ACT port located on
the pre-membrane oxygenator diamond. PTT is monitored every 6 h during ECMO. Our target PTT level is
80–110 s. If ACT level is greater than the target range,
we decrease the heparin infusion by 5–15 units/h. If the
ACT is 20–25 s below the lower end of the target level
or PTT is <65 s, a heparin bolus of 20 units/kg is given
and infusion is increased by 5–15 units/h. If PTT
level is >140, 10 ml/kg of fresh frozen plasma (FFP)
is given. Platelet levels are checked every 6 h to a target value of >100,000, if less; platelet transfusion of
10 ml/kg is given. Fibrinogen level is checked every 12 h
to a target value of >100 mg/dL. If the level is lower than
the target value, cryoprecipitate is given to the patient.
Heparin drip is increased by 5–15 units/h during platelet
infusion and reduced to previous rate once the platelet
infusion is completed.
Data were also collected for heart rate, mean arterial
pressure (MAP) changes as well as minimum and maximum pH, PCO2, PaO2, and lactate levels. All infants
were placed on ECMO support through neck cannulation. Decision for VA ECMO was based on patient’s
clinical status, persistent and significant acidosis, higher
level of respiratory support and hypoxemia, or signs of
poor end organ perfusion. The hypoxia is described as
having oxygenation index ≥40 for ≥4 h or persistently
high oxygenation index for more than 12 h or PaO2 ≤40
despite maximum medical management.
Management of ICH on ECMO in our institution:
Patients are decannulated if the intracranial hemorrhage is
associated with profound clinical deterioration. If they remain asymptomatic, we maintain the lowest ACT possible
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(180–200) and repeat head ultrasound (HUS) more frequently. If ICH progresses, decannulation is considered as
soon as full mechanical ventilator support can be achieved
even if the settings are very high.
All infants had HUS evaluation prior ECMO cannulation. Baseline head US evaluations were negative for
ICH before initiation of ECMO support. Daily HUS
study was obtained to assess intracranial bleeding during
ECMO. All ICH cases were diagnosed by HUS, and no
CT scan were performed. All patients in the study were
placed on prophylactic antibiotics. There was no mortality
in our study population.
For statistical analyses, two-sample t test and chi-square
tests were used and the null hypothesis was rejected at a
p ≤ 0.05. In all statistical analyses, MinitabR (State College,
PA 16801, USA) Program was utilized.
The study received approval from IRB of North Shore
LIJ Health System.

Results
A total number of 32 subjects were included in the
study. The primary reason for initiation of ECMO in all
patients was the persistent hypoxia unresponsive to conventional therapy. Eleven patients were identified to have
ICH by routine daily ultrasound, and 21 patients were
without ICH. Demographic data is shown in Table 1.
Mean duration of ECMO in hours was not significantly
longer in the ICH group compared to the non-ICH
group (p = 0.680). All factors and variables were measured
and compared before ICH occurrence on both groups.
The data on the maximum ACT levels and heparin infusion doses for 120 h on ECMO are shown in Table 2. We
presented hourly ACT levels and heparin infusion doses
for the two groups during the first 12 h on ECMO and
found no statistical significance between the two groups
(Table 2).
However, comparison of coagulation profiles indicated
that the mean minimum platelet count and fibrinogen
levels were significantly lower in the ICH group as demonstrated in Table 3 (p = 0.005 and 0.009, respectively).
We found no statistical difference between a PTT, PT
and INR values between the groups (Table 3). Similarly,
Table 1 Patients demographic data
p values

ICH

No ICH

Total number of patients: 32

11 (34%)

21 (66%)

Gestational age in weeks
(mean ± SD)

38.1 ± 1.2

38.3 ± 1.8

0.743

Gender (F/M)

4/7

5/16

0.453

Weight in kg (mean ± SD)

3.3 ± 0.2

3.4 ± 0.6

0.602

Type of ECMO (VV/VA)

4/7

9/12

0.722

Duration of ECMO in hour
(mean ± SD)

183 ± 14

164 ± 11

0.680

mean volumes of platelet, fresh frozen plasma and
cryoprecipitate transfusions for both groups were not
significantly different between two groups (Table 3).
Mean arterial pressure measurements were higher in the
ICH group compared to the non-ICH group (69.36 ± 4.34
vs. 64.19 ± 4.86 mmHg with a p = 0.006) (Table 4). Minimum and maximum heart rate measurements were not
statistically different between the two groups (Table 4).
Similarly, the minimum pH values, maximum lactate
levels, highest PaCO2, and lowest PaO2 in two groups did
not differ significantly (Table 4).

Discussion
Our results showed that low fibrinogen and platelet
levels as well as higher MAP were associated with developing ICH. In this report, low fibrinogen level for the
first time in the literature was identified as a risk factor
for ICH for PPHN patients. Previous studies indicated
the risk factors for developing ICH as low platelet
counts, difficulty in maintaining platelet counts and
ACT levels in normal range with frequent platelet transfusions and frequent adjustments to the heparin drip
rate [9-11]. In our study, both groups had similar mean
hourly ACT levels as well as heparin infusion doses during the first 12 h on ECMO. Additionally, the maximum
ACT and heparin infusion doses per day for the first 5 days
were similar. Mean volumes of platelet transfusions between the two groups were not statistically significant
(p = 0.812).
Significantly, however, lower fibrinogen levels in the
ICH group compared to the non-ICH group were noticed (p = 0.009). In one study, Kasirajan pointed to
lower fibrinogen levels in adult patients with ICH during
ECMO; nevertheless, the results did not reach to a statistical significance. In that study, there was a strong correlation between thrombocytopenia and risk of ICH
[12]. To our knowledge, this is the first report to show
low fibrinogen levels as a risk factor in infants for ICH
on ECMO support. Consumption of coagulation factors
by the ECMO circuit has been known to occur, and the
consequent deposition of fibrin which might cause the
transfer of the patient to newly primed circuit has been
reported [7,13].
In a previous study, metabolic acidosis, bicarbonate
use or inotrope/vasopressor requirement, cardiopulmonary resuscitation, or a left ventricular-assisted device
before initiation of extracorporeal life support were identified as risk factors for developing neurological complications on ECMO [14]. In our study, minimum pH
levels for both groups were similar during the course of
ECMO support and highest lactate levels were not
significantly different in both groups. We identified that
increased MAP were related to ICH (p = 0.006). One can
postulate that a lower target MAP may help prevent
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Table 2 Maximum daily ACT values and maximum heparin infusion doses for each day*
ACT in seconds (mean ± SD)

Max. heparin (mean ± SD)

Group

Day 1

Day 2

Day 3

Day 4

Day 5

ICH

318.3 ± 54.8

260.8 ± 57.0

259.3 ± 62.2

264.8 ± 58.5

271.4 ± 57.3

No ICH

313.7 ± 61.2

259.3 ± 29.0

252.2 ± 42.1

257.0 ± 33.2

255.6 ± 45.9

ICH

32.1 ± 11.9

34.0 ± 11.4

40.2 ± 16.3

39.8 ± 11.3

37.8 ± 12.6

No ICH

36.2 ± 11.8

37.6 ± 9.08

39.95 ± 7.93

43.5 ± 12.5

38.4 ± 13.9

*p values for maximum daily ACT values and maximum heparin infusion doses for each day were not statistically significant.

ICH, as long as an adequate tissue perfusion is
maintained.
Systemic arterial hypertension can result in increasing
cerebral blood flow in hypoxic newborns if autoregulatory
mechanisms decreased or lost. An abnormality in cerebral
blood flow is a risk factor for ICH in newborn. One experimental animal study showed that systemic hypertension resulted in germinal matrix hemorrhage [15].
Gestational age was reported to be the most significant
predictor of ICH, especially if it is less than 34 weeks
[16]. Our study did not support that finding; mean
gestational age was 38.1 ± 1.2 weeks in the ICH group
vs. 38.3 ± 1.8 weeks for the non-ICH group (Table 1).
Hervey-Jumper and colleagues [17] reported that infants
less than 30 days of age and requiring ECMO support
for cardiac etiology were more prone to have ICH on
ECMO. In our study, all patients were less than 30 days
of age with a mean age of 2.3 days in both groups at the
start of ECMO, and not differing significantly between
study groups (p = 0.947).
Previously, sepsis as a primary diagnosis was indicated
to form an increased risk for ICH in infants compared
to non-septic infants, and among septic infants, timing
of ICH was reported at less than 72 h on ECMO [18]. In
the current study, none of our patients had sepsis, and
consequently, sepsis was not a factor for this study.

In our study, the incidence of ICH (34%) is relatively
higher compared with ELSO registry data (11%) [8].
Obviously, the one explanation would be the difference in the study group reported here and the ELSO
registry patients. One might argue that we report from a
subpopulation of the patients undergoing ECMO support
procedure and the overall incidence would closely follow
the national data.
In recent studies, the search for a better test for monitoring the coagulation status of ECMO patients addressed [19,20]. Anti-Xa test has been indicated as a
better correlate for heparin dosing compared to ACT
and aPTT tests. Also, antithrombin III test and use of
thromboelastography have been mentioned. However,
the studies are reported from relatively small group of
patients, and further detailed investigations with additional parameters including anti-Xa, antithrombin III,
fibrin degradation products, or d-dimers might be useful
to establish the utility of these measurements.
One limitation of our study was the small number of
patient population with 32 subjects. Furthermore, we
reviewed the patient’s data retrospectively. However, it
should be pointed out that our data obtained from relatively homogenous group of patients and the study
covers a period of 14 years at a high volume reference
PICU in a large university medical center, indicating the

Table 3 Data related to coagulation profiles

Table 4 Arterial blood gas analysis and changes in vital
signs

No ICH
(mean ± SD)

p values

Min. platelet (Thousand/μl) 37.4 ± 18.3

60.4 ± 23.3

0.005

Max. platelet (Thousand/μl) 116.4 ± 18.9

140.7 ± 35.4

0.017

Min. PTT (s)

60.6 ± 19.8

0.101

ICH
(mean ± SD)

50.4 ± 13.9

ICH
(mean ± SD)

No ICH
(mean ± SD)

p values

Lowest pH

7.22 ± 0.12

7.24 ± 0.13

0.701

Highest pH

7.48 ± 0.02

7.49 ± 0.06

0.818

Max. PTT (s)

165 ± 48.7

173 ± 33.9

0.661

Lowest PaCO2 (mmHg)

32.73 ± 7.02

30.10 ± 6.6

0.318

Min. PT (s)

13.18 ± 1.33

13.38 ± 1.96

0.737

Highest PaCO2 (mmHg)

65.90 ± 27.9

61 ± 17.5

0.601

Max. PT (s)

23.09 ± 7.23

20.24 ± 6.54

0.288

Lowest PaO2 (mmHg)

52.2 ± 16.7

45.6 ± 16.2

0.298

Min. fibrinogen (mg/dl)

115 ± 43.8

175 ± 74.8

0.009

Highest PaO2 (mmHg)

189.7 ± 61.7

179.4 ± 83.9

0.695

Max. fibrinogen (mg/dl)

326 ± 119

336 ± 83.9

0.809

Low lactate (mmol/l)

1.143 ± 0.51

1.04 ± 0.59

0.704

Min. INR

1.14 ± 0.93

1.13 ± 0.13

0.714

High lactate (mmol/l)

5.76 ± 4.41

3.75 ± 3.91

0.335

Max. INR

1.94 ± 0.67

1.61 ± 1.50

0.171

Min. HR (bpm)

105.6 ± 24.2

101.7 ± 14.5

0.626

Platelet V. (ml)

400.90 ± 314.80 434.30 ± 407.19 0.812

Max. HR (bpm)

169.2 ± 20.9

176.9 ± 15.7

0.301

FFP V. (ml)

107.60 ± 89.20

86.80 ± 44.15

0.380

Min. MAP (mmHg)

40.09 ± 6.85

36.52 ± 5.01

0.148

Cryoprecipitate V. (ml)

15.45 ± 20.18

7.85 ± 21.5

0.346

Max. MAP (mmHg)

69.36 ± 4.34

64.19 ± 4.86

0.006
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relative scarcity of patients with similar demographics
for this type of analysis. Nevertheless, prospective multicenter studies with a larger patient size might provide a
stronger support to the present findings, and the inclusion of larger number of patients on a prospective investigation would eliminate some of the drawbacks that
might be resulting from limits on patient number.
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10.

11.

12.

Conclusions
Despite the limitations, our study demonstrated that
several factors such as low fibrinogen level, low platelet
counts, and high MAP might be associated in development of ICH on ECMO patients. These associations are
significant, and some such as low fibrinogen levels are
reported for the first time in the literature.
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